Deutsche Bank Suspends Coverage on Valeant Pharma (VRX)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/6/2026
- S&P 500, Dow futures steady as MidEast deal in focus; chips stumble
- SpaceX tumbles amid AI spending concerns; Musk outlines $1 trillion revenue target
- AMD shares slide 8% after Musk flags plans to buy Nvidia chips for SpaceX
- AZN spikes 6% after report it denies AstraZeneca-BMS merger talks
- New report warns China transceiver ban would hurt U.S. AI giants
- Salesforce president Srini Tallapragada steps down, becomes advisor
- Sandisk (SNDK) Tops Q4 EPS by $4.66, Offers Guidance
- EverCommerce names Alex Goor as new CEO, founder steps down
- Crude Inventory Rose 2.5 Million Barrels Last Week - EIA
- AMD shares slide 8% after Musk flags plans to buy Nvidia chips for SpaceX
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
- After-Hours Movers: SPCX, AMD, ANET, PINS, APPS, UPST, ZETA, BKNG, LCID, CPNG, MTCH
- After-Hours Stock Movers: PLTR, SNAP, ON, ICHR, WGS, WHR
- After-Hours Stock Movers: AAPL, AMZN, COIN, RBLX, RDDT, AXTI, FND, WU, GDDY
- After-Hours Stock Movers: META, MSFT, CMG, SBUX, CVNA, LRCX, FTNT, QCOM, TDOC
UPDATE: Canaccord Genuity Downgrades Valeant Pharmaceuticals (VRX) to Hold
March 2, 2016 6:55 AM EST(Updated - March 2, 2016 1:08 PM EST)
Canaccord Genuity downgraded Valeant Pharmaceuticals (NYSE: VRX) from Buy to Hold and lowered its price target to $75 (from $125). Valeant recently confirmed that it has several ongoing investigations, including investigations by the US Attorneys Offices for Massachusetts and the Southern District of New York, the SEC, and Congress.
Analyst Neil Maruoka commented... More
Valeant Pharma (VRX) Pares Earlier Decline
March 1, 2016 2:28 PM ESTValeant Pharma (NYSE: VRX) pared earlier declines to trade lower by only 1.3%.
Valeant (VRX) PT Cut to $106 at Jefferies
March 1, 2016 8:16 AM ESTJefferies analyst David Steinberg lowered his price target on Valeant Pharmaceuticals (NYSE: VRX) to $106.00 (from $172.00) while maintaining a Buy rating.
Steinberg commented, "With the return of CEO Mike Pearson, a critical issue has been addressed. However, a host of equally critical questions have... More
SEC Investigation Extends Valeant Pharma's (VRX) Road to Confidence - BMO
March 1, 2016 7:18 AM ESTBMO Capital analyst, Alex Arfaei, takes a stab at valuing Valeant (NYSE: VRX) while acknowledging the limited visibility into the financial impact of the investigation. No change to Market Perform rating.
The SEC investigation and the form 10-K filing delay increase concerns about the integrity of Valeants financial reporting. It is very difficult to predict the potential range of outcomes of this... More
Valeant Pharma (VRX) Provides Statement on SEC Investigation
February 29, 2016 4:41 PM ESTValeant Pharma (NYSE: VRX) said:
"In response to media inquiries, Valeant confirmed that it has several ongoing investigations, including investigations by the US Attorneys Offices for Massachusetts and the Southern District of New York, the SEC, and Congress. With respect to the SEC... More
Valeant Pharma (VRX) Affirms Receipt of SEC Subpoena
February 29, 2016 4:40 PM ESTValeant Pharma (NYSE: VRX) issued the following statement on Monday:
"In response to media inquiries, Valeant confirmed that it has several ongoing investigations, including investigations by the US Attorneys Offices for Massachusetts and the Southern District of New York, the SEC, and... More
Valeant Pharma (VRX) Says It's Under Investigation by SEC
February 29, 2016 3:36 PM EST(Updated - February 29, 2016 3:38 PM EST)
Valeant Pharma (NYSE: VRX) said it's under investigation by the SEC, according to Bloomberg, citing spokesperson Laurie Little. The probe is said to be separate from the Salix investigation.
"In response to media inquiries, Valeant confirmed that it... More
